- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05431595
Håndtering af agiteret delirium med neuroleptika og anti-epileptika som en neuroleptisk sparestrategi
To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with cancer. This double-blind, randomized clinical trial aims to provide evidence on various therapeutic options for palliating delirium, thereby reducing delirium-related distress and ultimately alleviating suffering.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Objectives:
Primary objective:
Compare the effect of scheduled haloperidol, chlorpromazine, valproate and placebo (non-pharmacological interventions alone) on the frequency of breakthrough restlessness over 72 hours in patients with agitated delirium seen by the palliative care consultation team. Our working hypothesis is that haloperidol, chlorpromazine, and valproate will lead to fewer episodes of breakthrough restlessness than placebo.
Secondary Objective #1:
Compare the effects of scheduled haloperidol, chlorpromazine, valproate and placebo on (1) RASS-PAL, (2) need for dose escalation, (3) perceived comfort by caregivers and bedside nurses, (4) delirium severity (Memorial Delirium Assessment Scale), (5) delirium-related distress in caregivers and nurses (Delirium Experience Questionnaire), (6) delirium recall in patients (Delirium Recall Questionnaire), (7) symptom expression (Edmonton Symptom Assessment Scale), (8) adverse effects, and (9) survival. Our working hypothesis is that haloperidol, chlorpromazine, and valproate are superior to placebo (non-pharmacologic interventions alone) in improving delirium-related outcomes.
Secondary Objective #2:
Estimate the efficacy of non-pharmacologic interventions alone on breakthrough restlessness. Our working hypothesis is that patients in the placebo group will require fewer breakthrough doses in the 72 hours after implementation of non-pharmacological interventions
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- MD Anderson Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- [Patients] Diagnosis of advanced cancer (defined as locally advanced, metastatic recurrent, or incurable disease)
- [Patients] Seen by palliative care inpatient consultation team
- [Patients] Delirium as per DSM-5 criteria
- [Patients] Hyperactive or mixed delirium with either a rescue medication order or any non-pharmacologic measures (e.g. sitter, restraints) for agitation, restlessness, or delirium
- [Patients] Age 18 years or older
- [Patients] Permission from clinician from primary team to enroll
- [Family Caregivers] Patient's spouse, adult child, sibling, parent, other relative, or significant other (defined by the patient as a partner)
- [Family Caregivers] Age 18 years or older
Exclusion Criteria:
- [Patients] On scheduled haloperidol >4 mg/d, chlorpromazine >100 mg/d, or valproate >750 mg/d
- [Patients] History of myasthenia gravis, acute narrow-angle glaucoma, or hepatic encephalopathy as documented in chart
- [Patients] Hepatic dysfunction (unresolved AST or ALT >2.5x ULN, bilirubin >1.5x ULN or INR >1.5 within past month)
- [Patients] History of neuroleptic malignant syndrome as documented in chart
- [Patients] Active seizure disorder within past month as documented in chart
- [Patients] History of Parkinson's disease or dementia as documented in chart
- [Patients] History of prolonged QTc interval (>500 ms) if documented by most recent ECG within the past month
- [Patients] Hypersensitivity to haloperidol, chlorpromazine, or valproate as documented in chart
- [Patients] Pancreatitis within past month as documented in chart
- [Patients] Currently on lamotrigine, phenobarbital, or carbamazepine
- [Patients] Physical signs of impending death such as respiration with mandibular movement and death rattle
- [Patients] Pregnancy as documented in chart
- [Patients] Active COVID-19 infection as documented in chart
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Group 1
Participants will receive haloperidol by vein every 12 hours (or more often, as needed). |
Given by Vein (IV) |
|
Eksperimentel: Group 2
Participants will receive chlorpromazine by vein every 12 hours (or more often, as needed). |
Given by Vein (IV)
Andre navne:
|
|
Eksperimentel: Group 3
Participants will receive valproate by vein every 12 hours. |
Given by Vein (IV)
Andre navne:
|
|
Eksperimentel: Group 4
Participants will receive placebo every by vein every 12 hours. |
Given by Vein (IV) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Edmonton Symptom Assessment Scale Questionnaire
Tidsramme: through study completion, an average of 1 year
|
Edmonton Symptom Assessment Scale (ESAS)-score scale ranges from (0-10) No pain-0/Worse Possible Pain 10 (0-10) |
through study completion, an average of 1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: David Hui, MD, M.D. Anderson Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Psykiske lidelser
- Forvirring
- Neuroadfærdsmæssige manifestationer
- Neurokognitive lidelser
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Delirium
- Epilepsi
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, smeltet ring
- Fedtsyrer
- Lipider
- Syrer, acyklisk
- Carboxylsyrer
- Pentanesyrer
- Valerates
- Fedtsyrer, flygtige
- Heterocykliske forbindelser, 3-ring
- Butyrophenoner
- Ketoner
- Phenothiaziner
- Valproinsyre
- Klorpromazin
- Haloperidol
Andre undersøgelses-id-numre
- 2022-0172
- NCI-2022-05252 (Anden identifikator: NCI-CTRP Clinical Trial Reporting Registry)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .